Search Results
Feb 18, 2026, 11:14 ET Cancer Stress Protein Helps Tumors Hide From Immunity
with an existing immunotherapy drug worked even better, extending survival in mice with aggressive lung cancer."Our results provide a clear rationale for developing therapies that target LCN2 in lung cancer patients," said co-corresponding study author
More news about: NYU Langone Health System
Feb 18, 2026, 09:00 ET Nation's Leading Oncology and Value-Based Care Experts Join Daymark Health's Clinical Advisory Board
Cardinale Smith, Chief Medical Officer at the Memorial Sloan Kettering Cancer Center, is a thoracic medical oncologist and one of the nation's preeminent lung cancer specialists. Dr. Smith is also a renowned expert and research leader in palliative care, community engaged interventions, and managing cancer
More news about: Daymark Health
Feb 18, 2026, 08:46 ET Center for Asbestos Related Disease, Inc. (CARD) Invites Community Members to Attend an Open House and Ribbon Cutting Celebration
organization hopes the event will help clarify that screening services remain available and encourage participation in its free asbestos health screening and lung cancer screening programs.In addition to celebrating the ribbon cutting, CARD will introduce its new healthcare provider and welcome representatives
More news about: Center for Asbestos Related Disease, Inc. (CARD)
Feb 18, 2026, 08:30 ET OncoHost Publishes Landmark Study in JPBA Demonstrating Serum-Plasma Proteomic Bridging, Expanding Biomarker Research Capabilities
PROphet® platform—an AI-powered, plasma proteomics-based model designed to predict immunotherapy outcomes in patients with non-small cell lung cancer (NSCLC).When applied to scaled serum proteomic measurements, the PROphet model maintained predictive accuracy. Clinical benefit classification
More news about: OncoHost
Feb 18, 2026, 08:30 ET "I Feel Energized And Satisfied Without Crashing And No Jitters Or Bloating" -- Gundry MD Proplant Complete Shake Earns Rave Reviews As A Top Plant-Based Protein Powder
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Currently, he's the medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he's spent the past 25 years helping people restore
More news about: Gundry MD
Feb 18, 2026, 08:00 ET Synchrony Medical Secures $5M Funding to Fuel Commercial Expansion of its At-Home Airway Clearance Device for Chronic Respiratory Disease
expansion, support ongoing clinical research and product development, and broaden patient access to LibAirty™. For millions living with chronic lung conditions, airway clearance is essential to managing symptoms, preventing infections, and slowing disease progression. The LibAirty™ system delivers
More news about: Synchrony Medical
Feb 18, 2026, 07:30 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
reaction occurs, permanently discontinue RYBREVANT®.Interstitial Lung Disease/PneumonitisRYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.RYBREVANT FASPRO™ with LAZCLUZE®In
More news about: Johnson & Johnson
Feb 17, 2026, 16:05 ET TransMedics to Present at Upcoming March Investor Conferences
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled
More news about: TransMedics Group, Inc.
Feb 17, 2026, 16:01 ET HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
hyaluronidase-lpuj) for the treatment of patients with epidermal growth factor receptor ("EGFR")-mutated locally advanced or metastatic non-small cell lung cancer ("NSCLC").In December 2025, Janssen received approval from the National Medical Products Administration in China for RYBREVANT™ FASPRO
More news about: Halozyme Therapeutics, Inc.
Feb 17, 2026, 11:00 ET FDA Approves FILKRI™ (filgrastim-laha), Accord BioPharma's Biosimilar to NEUPOGEN® (filgrastim)
be carefully considered. Patients with Breast and Lung Cancer: MDS and AML have been associated with the use of filgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these
More news about: Accord BioPharma
Feb 17, 2026, 09:00 ET Blue Clay Health Launches Patient and Family Advisory Committee Chaired by Dr. James Gillespie
diagnoses as a teenager with a prognosis of fourteen days to live, Swarner has since completed the "7 Summits" with only one functioning lung."Climbing Everest with one lung is a lot like navigating a complex health crisis; it requires a mindset of absolute hope and resilience," said Sean Swarner. "Blue
More news about: Blue Clay Health
Feb 17, 2026, 09:00 ET Function and Erewhon Challenge the Meaning of "Healthy" with "The World's Healthiest Smoothie?"
advanced MRI is designed to detect signs of cancers, unruptured aneurysms, endometriosis, stroke, and more, while the CT scan can search for signals of lung cancer, plaque in the heart, and other serious health conditions. Function is redefining what it means to take control of your health.ABOUT
More news about: Function Health
Feb 17, 2026, 08:56 ET Green Hero Foundation Marks One Year Anniversary with Nationwide Wildlife Recovery and 373,000 Trees Planted
reforestation does more than just capture carbon, it rebuilds communities and coastlines.The report details how the Foundation is helping to "re-lung" the Earth, with verified planting sites including:The Mangroves of Tanzania & Kenya: Restoring the "blue carbon"
More news about: Restaurantware
Feb 17, 2026, 08:00 ET FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
The Journal of Clinical Oncology in 2023.About Non-Small Cell Lung Cancer (NSCLC)Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.14,15 The main subtypes of NSCLC are adenocarcinoma, squamous
More news about: Johnson & Johnson
Feb 17, 2026, 08:00 ET Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
Aiming to introduce a new therapeutic strategy for overcoming chemotherapy resistance in lung cancer due to increased expression of cellular pathwaysREHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ --
More news about: Evogene
Feb 17, 2026, 08:00 ET Mepolizumab May Be Protective Against Small Airway Disfunction Exacerbation Risks in Children
option to optimize patient care."In a secondary analysis of a pediatric randomized controlled trial, we assessed the association between baseline lung function impairment (measured by spirometry and impulse oscillometry) and exacerbation risk. Greater baseline obstruction was associated with higher
More news about: American Academy of Allergy, Asthma & Immunology (AAAAI)
Feb 17, 2026, 07:45 ET TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
either as monotherapy (n=24) or in combination with pembrolizumab (n=15) among patients with advanced, therapy refractory cancers, including breast, lung, colorectal, and ovarian cancer. The purpose of the study was to investigate its safety profile and determine the recommended Phase 2 dose. The drug
More news about: TuHURA Biosciences, Inc.
Feb 17, 2026, 07:42 ET Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
Actinium's lead product candidate, is a novel, first-in-class, and multi-indication Actinium-225 (Ac-225) in development for prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer. The antigen specifically targeted by ATNM-400 is highly expressed in metastatic castration-resistant prostate cancer
More news about: Actinium Pharmaceuticals, Inc.
Feb 17, 2026, 06:50 ET Labcorp Announces 2025 Fourth Quarter and Full Year Results
timely patient care.Expanded access to its molecular residual disease (MRD) testing for stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer to help clinicians detect cancer recurrence earlier than traditional imaging.Launched several new consumer-initiated
More news about: Labcorp Holdings Inc
Feb 17, 2026, 06:00 ET IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
'26Initiation of IDE849 (DLL3 TOP1 ADC) monotherapy registrational study in the second line/refractory setting (2L+) of small cell lung cancer (SCLC) and/or neuroendocrine carcinomas (NEC) targeted by the end of 2026Preliminary clinical data update from IDEAYA-sponsored
More news about: IDEAYA Biosciences, Inc.
Feb 16, 2026, 10:31 ET Healthcare Predictive Analytics Market to Reach $128.2 Billion by 2033 Globally, at 24.3% CAGR: Allied Market Research
WorldwideIn February 2024, Mount Sinai's dedicated team of researchers were granted $4.1 million by the National Heart, Lung, and Blood Institute (NHLBI) at the esteemed National Institutes of Health (NIH) to pioneer artificial intelligence (AI) models aimed at forecasting
More news about: Allied Market Research
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
most striking data for targeted adjuvant therapy in lung cancer," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "Building on the adoption of targeted therapies for early-stage patients with EGFR- and ALK-driven lung cancer, we hope these results further accelerate the
More news about: Eli Lilly and Company
Feb 16, 2026, 06:00 ET P-Cure Announces First-Ever Prospective Clinical Results of Gantry-Less Upright Proton Therapy for Lung Cancer Re-Irradiation
VMAT, while maintaining equivalent target coverage. Upright positioning increased total lung volume by an average of 9.8%, reinforcing the anatomical and functional rationale for upright thoracic treatment in lung cancer patients.These findings confirm that gantry-less upright proton therapy can
More news about: P-Cure
Feb 15, 2026, 19:10 ET CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
tumor indications, including but not limited to:Non-small cell lung cancer (NSCLC)Colorectal cancer (CRC)Triple-negative breast cancer (TNBC)Extensive-stage small cell lung cancer (ES-SCLC)Platinum-resistant ovarian cancer (PROC)Initial
More news about: CStone Pharmaceuticals
Feb 14, 2026, 00:15 ET Coreline Soft and INFINITT North America Deliver True "Zero-Click" AI Workflow to U.S. Radiology Practices
LCS, a solution that has redefined the 'First Reader' role in lung cancer screening. Attendees can also explore AVIEW Lung Texture for ILD and AVIEW COPD, with a focus on Opportunistic Screening—simultaneously assessing lung cancer, COPD, and cardiovascular risk from a single low-dose
More news about: Coreline Soft